Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depres...
Product Name : SDI-118
Product Type : Other Small Molecule
Upfront Cash : $130.0 million
January 03, 2022